Zobrazeno 51 - 60
of 73
pro vyhledávání: '"Ian Hirsch"'
Autor:
Stephen F. Hobbiger, Davide Luciani, Christine E. Hallgreen, Shahrul Mt-Isa, Lawrence D. Phillips, George Quartey, Deborah Ashby, Kimberley Hockley, Ian Hirsch, Isabelle Stoeckert, Torbjörn Callréus, Nan Wang, Ioanna Tzoulaki, Georgy Genov, Alain Micaleff, Sinan B. Sarac
Publikováno v:
Pharmacoepidemiology and Drug Safety. 23:667-678
Background The need for formal and structured approaches for benefit-risk assessment of medicines is increasing, as is the complexity of the scientific questions addressed before making decisions on the benefit-risk balance of medicines. We systemati
Publikováno v:
Pneumologie. 72:S15-S16
Publikováno v:
Revue Française d'Allergologie. 59:294
Introduction L’asthme est frequemment d’origine allergique. Nous avons compare les caracteristiques demographiques et cliniques des patients avec et sans maladie allergique inclus dans les etudes de phase III SIROCCO ( NCT01928771 ) et CALIMA ( N
Publikováno v:
Journal of Allergy and Clinical Immunology. 143:AB100
Publikováno v:
Annals of Allergy, Asthma & Immunology. 119:S55-S56
Publikováno v:
Open Journal of Rheumatology and Autoimmune Diseases. :92-103
Introduction: Fatigue is an important fibromyalgia (FM) symptom, but existing measures of fatigue are unlikely to meet regulatory standards for clinical trial use. We describe the development and validation of the Daily Diary of Fatigue Symptoms—Fi
Publikováno v:
Pharmaceutical Statistics. 10:250-256
The minimum clinically important difference (MCID) between treatments is recognized as a key concept in the design and interpretation of results from a clinical trial. Yet even assuming such a difference can be derived, it is not necessarily clear ho
Autor:
Paul Newbold, Mitchell Goldman, J. Mark FitzGerald, Ian Hirsch, Yanping Wu, Eugene R. Bleecker, Michael E. Wechsler, James Zangrilli, Andrew Menzies-Gow
Publikováno v:
European Respiratory Journal. 52:1800936
Benralizumab is an anti-eosinophilic monoclonal antibody that reduces exacerbations and improves lung function for patients with severe, uncontrolled asthma with eosinophilic inflammation. We evaluated the impact of baseline factors on benralizumab e
Publikováno v:
Clinical Therapeutics. 32:1618-1632
Esreboxetine is an investigational, highly selective norepinephrine reuptake inhibitor that has been reported to have antinociceptive effects in preclinical pain models.This study assessed the efficacy and safety profile of esreboxetine in the manage
Publikováno v:
Annals of Allergy, Asthma & Immunology. 120:504-511.e4
Background Patients with severe asthma can have eosinophilic inflammation and/or allergen sensitization. Benralizumab is an anti-eosinophilic monoclonal antibody indicated for add-on maintenance treatment of patients with severe asthma aged 12 years